![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Ilya Tsyrlov | |
---|---|
Born | Ilya Borisovich Tsyrlov |
Nationality | American-Russian |
Alma mater | |
Known for |
|
Scientific career | |
Fields | |
Institutions | |
Thesis | Drug-Metabolizing Enzyme Systems of Normal and Cirrhotic Liver (1973); “Induction by Xenobiotics and Functional Peculiarity of Membrane-Bound Monooxygenases”. [1] (1983) |
Ilya Borisovich Tsyrlov is a Russian-American biochemist, molecular toxicologist and virologist. He is known for his studies and research on enzymology, drug metabolism, environmental toxicology, bioinformatics, virology, and cancer. Tsyrlov has authored 4 monographs, and co-authored over 280 publications on microsomal, purified and recombinant monooxygenases, and mechanisms of CYP induction by xenobiotics. [2] [3]
Tsyrlov graduated in 1970 from Novosibirsk State Medical Academy, USSR, and received a PhD degree in biochemistry from the same institution (1973). In 1983 Tsyrlov earned higher Doctor of Sciences degree (biochemistry) from the Institute of Experimental Medicine, Russian Academy of Sciences. [1] He held various positions at Institute of Molecular Biology and Biophysics in Russian Academy of Sciences, including head of laboratory and chair of the Department of Xenobiochemistry. In 1990, the US National Institutes of Health (NIH) hired him for a position of a senior enzymologist at the Laboratory of Molecular Carcinogenesis (headed by Harry Gelboin), National Cancer Institute. Since 1994 he held positions of research associate professor/professor/visiting professor at the Department of Medicine, Mount Sinai School of Medicine (Icahn School of Medicine at Mount Sinai), New York, NY. [3]
In 2005, Tsyrlov founded Xenotox, Inc, a life sciences consulting company implementing an earlier discovered site-directed synthesis of long-acting drugs, and studying the transactivation of the human herpesviruses by body burden dioxins. [3] He was elected an emeritus member of International Society for Study of Xenobiotics (ISSX). [4] Dr. Tsyrlov has lectured and keynoted at research seminars and conferences on many occasions. [5] [1]
Tsyrlov used protonophores and probes affecting arachidonic acid of phospholipids in endoplasmic reticulum to show different compartmentalized hydrobobic clusters coupled with substrate-binding and electron-accepting moieties of membrane bound cytochrome P450 (CYP). [6] [7] Following up discovery of mechanism for “phenobarbital-type” induction of CYP2B6 and applicability of induced-fit hypothesis for membrane-bound enzymes, Tsyrlov with Konstantin Gerasimov prioritized method how to convert first-line antipyretic and antimalarial medicines into their long-acting forms. [8] [9] [10] [11] Tsyrlov and Dmitry Oshchepkov revealed numerous DREs in genes encoding XAP2 and HSP90AA1 chaperone proteins complexing with ligand-free cytoplasmic Ah-receptor. [12] Tsyrlov also conducted research on cDNA-expressed mammalian CYPs as preferred tests for major medical conditions. Tsyrlov revealed that human CYP1A2 is the catalyst of ethanol and uroporphyrinogen oxidation. Tsyrlov and Andrey Pokrovsky discovered TCDD ability to increase HIV-1 reverse transcriptase activity, HIV-1 p24 antigen, and augment HIV-1-LTR CAT construct in HIV-1-infected CD4+ cells, all mediated via the AhR/(bHLH)/Per-Arnt-Sim transcriptional pathway, [13] which thereafter has been shown to involve in trans-activation of some human herpesviruses. [14]